Search Result

Results for "

ras/raf

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (17) Ras (23) Akt (4) Annexin A (1) Antibiotic (2) Apoptosis (8) Atg8/LC3 (1) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Caspase (1) Cathepsin (1) CDK (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (2) Drug Isomer (1) ERK (5) Exosomes (1) FAK (1) Farnesyl Transferase (2) Ferroptosis (1) GLUT (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HSP (1) Interleukin Related (1) JNK (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (1) MEK (6) Microtubule/Tubulin (1) MMP (1) Molecular Glues (4) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (4) PERK (2) Phosphatase (1) Phospholipase (1) PI3K (4) PROTACs (1) Reactive Oxygen Species (ROS) (1) ROS Kinase (1) SHP2 (1) Src (1) STAT (1) TNF Receptor (2) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (33) Infection (3) Inflammation/Immunology (2) Metabolic Disease (1)

By Targets:

Raf (17)

Ras (23)

Akt (4)

Annexin A (1)

Antibiotic (2)

Apoptosis (8)

Atg8/LC3 (1)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

Caspase (1)

Cathepsin (1)

CDK (1)

Cyclin G-associated Kinase (GAK) (1)

Cyclophilin (2)

Drug Isomer (1)

ERK (5)

Exosomes (1)

FAK (1)

Farnesyl Transferase (2)

Ferroptosis (1)

GLUT (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HDAC (1)

HSP (1)

Interleukin Related (1)

JNK (1)

MAPKAPK2 (MK2) (1)

MDM-2/p53 (1)

MEK (6)

Microtubule/Tubulin (1)

MMP (1)

Molecular Glues (4)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (4)

PERK (2)

Phosphatase (1)

Phospholipase (1)

PI3K (4)

PROTACs (1)

Reactive Oxygen Species (ROS) (1)

ROS Kinase (1)

SHP2 (1)

Src (1)

STAT (1)

TNF Receptor (2)

Tyrosinase (1)

VEGFR (1)

By Research Areas:

Cancer (33)

Infection (3)

Inflammation/Immunology (2)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Raf Ras HRASLS SOS1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .

HY-N6796

Manumycin A 2 Publications Verification	Antibiotic Exosomes Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3	Infection Inflammation/Immunology Cancer
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the *Ras/Raf/ERK1/2* signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .

HY-158107

BBO-8520 1 Publications Verification	Ras	Cancer
BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS ^G12C with high oral availability. BBO-8520 has the characteristics of KRAS ^G12C (OFF) inhibitor and the function of blocking KRAS ^G12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS ^G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS ^G12C to the inactive (OFF) state. BBO-8520 can be used for the research of cancer .

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the *Ras/Raf/MEK/ERK* pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-158409

Pan-RAS-IN-2	Molecular Glues Ras Cyclophilin PERK	Cancer
Pan-rasin-2 (compound 6A) is an orally active molecular glues that targets *RAS. Pan-RAS-IN-2 inhibits pERK* (IC₅₀ in AsPC-1 cells: 0.3 nM). Pan-rasin-2 has significant inhibitory activity on cell proliferation of *RAS* mutant cell lines. Pan-rasin-2 can form ternary complexes with cyclophilin A (CYPA) and *RAS* (ON) proteins and the formation of ternary complexes can block the binding of *RAF* downstream of *RAS*, which has anti-tumor (such as colorectal cancer, pancreatic cancer) effects .

HY-141523

Vociprotafib RMC-4630; SHP2-IN-7	SHP2 Phosphatase	Cancer
Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the *RAS-RAF-MEK-ERK* signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice .

HY-N6670

Cefotetan	Antibiotic Raf ERK Ras MEK Bacterial	Infection
Cefotetan is a binding agent that targets *human Raf1 kinase inhibitor protein* (hRKIP). Cefotetan binds to hRKIP, reduces the binding space between hRKIP and Raf1 kinase, relieves hRKIP's inhibition of the *Ras/Raf1/MEK/ERK* signaling pathway, and enhances ERK phosphorylation. Cefotetan can be used to study diseases associated with dysregulated Ras/Raf1/MEK/ERK signaling pathways. Cefotetan is also a broad-spectrum antibacterial agent that disrupts cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). It is used to study bacterial infections such as bone, skin, urinary tract, and lower respiratory tract .

HY-N10503

Norartocarpetin	Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis	Cancer
Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC₅₀ value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC₅₀ value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells .

HY-15873A

FTI 276 TFA	Farnesyl Transferase Ras p38 MAPK	Cancer
FTI 276 TFA is a farnesyltransferase (FTase) inhibitor with an IC₅₀ of 0.5 nM, and it exhibits selectivity for FTase over geranylgeranyltransferase I (GGTase I). FTI 276 TFA blocks the farnesylation of *H-Ras* and *K-Ras4B, causes inactive Ras-Raf* complexes to accumulate in the cytoplasm, and inhibits constitutive MAPK activation. FTI 276 TFA reduces the number, incidence and volume of tumors, and restricts the growth of tumors expressing activated K-ras. FTI 276 TFA can be used in research related to pulmonary adenoma .

HY-138294

RAS/RAS-RAF-IN-1 2 Publications Verification	Ras Raf	Cancer
RAS/RAS-RAF-IN-1 is a potent *RAS* and *RAS-RAF* inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .

HY-15716

Kobe0065 4 Publications Verification	Ras Apoptosis	Cancer
Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

HY-123673

MCP110 2 Publications Verification	Ras Raf	Cancer
MCP110 is an inhibitor of *Ras/Raf-1* interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors .

HY-15717

Kobe2602 1 Publications Verification	Ras	Cancer
Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

HY-14947

Balamapimod MKI 833	MEK	Cancer
Balamapimod (MKI 833) is a reversible *Ras/Raf/MEK* inhibitor with potential anti-tumor activity.

HY-169212

I194496	PI3K Annexin A ERK VEGFR STAT Raf FAK Akt Ras	Cancer
I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC₅₀ of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active *RAF* inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-164365

PROTAC K-Ras Degrader-2	PROTACs Ras	Cancer
PROTAC K-Ras degrader-2 (compound 48) is a KRAS G12V PROTAC degrader with an IC₅₀ of 20-200 nM for KRAS G12V/RAF1. PROTAC K-Ras degrader-2 degrades SW620 KRAS G12V with a DC₅₀ of 1-10 nM. PROTAC K-Ras degrader-2 inhibits cell growth of SW620 3D cell with an IC₅₀ of ≤10 nM. PROTAC K-Ras degrader-2 can be used for the study of colorectal cancer (CRC) .

HY-157740

XSJ-10	HDAC	Cancer
XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC_{50_s} of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 .

HY-162536

Pan-RAS-IN-5	Molecular Glues Cyclophilin Ras	Cancer
Pan-RAS-IN-5 (compound 7A) is a molecular glues that can form a ternary complex with the proteins cyclophilin A (CYPA) and *RAS* (ON). The formation of the ternary complex can block the binding of *RAS* downstream of *RAF* and has anti-tumor effects .

HY-W1126467

RAS-IN-5	Ras	Cancer
RAS-IN-5 (Example 2) is a *RAS* inhibitor. RAS-IN-5 significantly inhibits the interaction between *RAF1* and active KRAS mutant protein or HRAS WT protein. RAS-IN-5 significantly inhibits the cell viability of KRAS, NRAS, and EGFR mutant cells. RAS-IN-5 can be used in the research of colorectal cancer, liver cancer, and non-small cell lung cancer .

HY-P10051

Cyclorasin 9A5	Ras Raf	Cancer
Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the *Ras-Raf* protein interaction with an IC₅₀ of 120 nM .

HY-177081

Envometinib	MEK	Cancer
Envometinib (Compound B) is a dual-MEK inhibitor that works through Deep Cyclic Inhibition (DCI). Envometinib has antitumor activity in various in vivo models. Envometinib can be studied in RAS and RAF mutated cancer such as colorectal cancer and melanoma .

HY-171777

Erufosine ErPC3; Erucylphosphohomocholine	PI3K Akt Ras Raf p38 MAPK	Cancer
Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC₅₀: 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia .

HY-E70765

RAF1 YDYD Recombinant Human Active Protein Kinase	Raf	Cancer
Ras-associated factor -1 (RAF1) belongs to the RAF protein kinases family, also known as C-Raf. RAF1 participates in Ras-RAF-MEK-ERk signaling pathway (MAPK signaling pathway), and transmits extracellular signals into the nucleus through cell membrane receptors, thereby mediating the expression of intracellular specific proteins and participating in the regulation of cell proliferation, differentiation, apoptosis, autophagy and other functions. RAF1 YDYD is a mutant of RAF1. RAF1 YDYD Recombinant Human Active Protein Kinase is a recombinant RAF1 YDYD protein that can be used to study RAF1 YDYD-related functions .

HY-142452

Pan-RAF kinase inhibitor 1	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of *Pan-RAF* kinase*. Pan-RAF* kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .

HY-103086

INU-152	Raf Autophagy Apoptosis	Cancer
INU-152 is a potent and selective *B-Raf* inhibitor. INU-152 reduces tumor cell proliferation, enhances autophagy, and induces apoptosis by inhibiting *B-Raf* activity. INU-152 exhibits significant cytotoxicity against cancer cells transformed with v-Ha-ras (Ras-NIH 3T3). INU-152 can be utilized in cancer research .

HY-P10051A

Cyclorasin 9A5 TFA	Ras Raf	Cancer
Cyclorasin 9A5 TFA is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the *Ras-Raf* protein interaction with an IC₅₀ of 120 nM .

HY-116664

DPQZ	Apoptosis Ras Raf Caspase	Cancer
DPQZ is an anti-tubulin agent that inhibits cell separation and induces cell cycle arrest at the G2/M phase. In addition, DPQZ induces caspase-dependent apoptosis of HSC-3 cells by inhibiting *Ras/Raf* and activating MAP kinase. DPQZ can be used in the study of oral cancer .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53	Cancer
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting *RAS-RAF* signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

HY-183674

MEK-IN-10	Molecular Glues MEK Raf PERK Ras p38 MAPK Apoptosis	Cancer
MEK-IN-10 is an orally active pan-MEK/RAF non-degrading molecular glue with an IC₅₀ of 782 nM against human MEK1. MEK-IN-10 blocks the phosphorylation of MEK and ERK, induces and stabilizes the *MEK1-RAF* complex, and disrupts the *RAS-MAPK* signaling pathway. MEK-IN-10 induces apoptosis in cancer cells and arrests cells at the G0/G1 phase. MEK-IN-10 induces tumor growth inhibition in mouse xenograft models. MEK-IN-10 can be used in the research of RAS-driven cancers, such as colorectal cancer and pancreatic cancer .

HY-175870A

(7R)-Eras-4001	Ras ERK	Cancer
(7R)-Eras-4001 is an orally active KRAS mutant inhibitor with remarkable selectivity for *H-RAS* and *N-RAS. (7R)-Eras-4001 effectively suppresses cancer cell viability by blocking downstream signaling pathways mediated by RAF* family proteins, inhibiting the formation of the KRAS ^G12D-RAF1 RBD complex and the phosphorylation of ERK1/2. (7R)-Eras-4001 induces tumor growth inhibition and regression in a dose-dependent manner, and also reduces plasma ERK1/2 phosphorylation levels. (7R)-Eras-4001 exerts a synergistic effect with anti-PD-1 Cetuximab (HY-P9905). (7R)-Eras-4001 can be used in research on non-small cell lung cancer, pancreatic cancer, colorectal cancer, and ovarian cancer .

HY-158107A

(4R)-BBO-8520	Drug Isomer Ras	Cancer
(4R)-BBO-8520 (Compound 314), an isomer of BBO-8520 (HY-158107), is a selective KRAS G12C inhibitor. BBO-8520 has the characteristics of KRAS ^G12C (OFF) inhibitor and the function of blocking KRAS ^G12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS ^G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS ^G12C to the inactive (OFF) state. (4R)-BBO-8520 can be used for the research of cancer .

HY-182614

BJ-2302	Src Cathepsin PI3K Akt Ras Raf ERK MMP	Cancer
BJ-2302 is a Src kinase inhibitor with an IC₅₀ of 3.23 μM, and inhibits cathepsin S (CTSS) activity .BJ-2302 binds to Src, suppresses PI3K/AKT and *Ras/Raf/ERK* pathways, and reduces CTSS and MMP-9 expression .BJ-2302 inhibits cancer cell invasion, metastasis, proliferation, and tumor growth .BJ-2302 does not induce cytotoxicity in normal breast epithelial cells .BJ-2302 can be used for the research of breast cancer and triple-negative breast cancer .

Cat. No.	Product Name	Target	Research Area